AMES, Iowa, Aug. 3 /PRNewswire-FirstCall/ -- BioForce Nanosciences (OTC
Bulletin Board: BFNH), manufacturer of the NanoArrayer(TM) System for
enabling new nanotechnology applications, has announced the placement of a
NanoArrayer in Paris at the Universite Pierre & Marie Curie (UPMC) for
technology evaluation by CNRS (Centre National de la Recherche
Scientifique), the French National Center for Scientific Research.
The NanoArrayer was installed in May in the laboratory of Dr. Fatiha
Nothias who noted, "Our plan is to use the unique printing capabilities of
the NanoArrayer to pattern proteins associated with cell morphology
establishment and migration." Dr Nothias said, "Our end goal is to
determine the consequences of the interactions of neurons and glial cells
with these patterned proteins." Other French research groups in the same
institute have expressed interest in utilizing the NanoArrayer to study how
cells sense their environment during the organization of the embryonic
Michael Lynch, Product Manager for the NanoArrayer, assisted with the
installation and training process. He noted that, "The NanoArrayer enables
protein patterning in the significantly small dimensions required to study
single cell growth and development important in Neuroscience, Cancer
Biology, Stem Cell Research, Genetic Disease and more." Lynch added, "This
installation also provided an opportunity to introduce NanoAndMore, our
European distributor for the NanoArrayer product line, to these new and
"This technology agreement partnership with UPMC and CNRS provides
BioForce with valuable new market applications of the NanoArrayer," noted
Kerry Frey, BioForce COO. "Our goal is continued growth into emerging new
bionanotechnology markets in Europe and this placement, our second overseas
this year, continues our progress."
About BioForce Nanosciences, Inc.
BioForce Nanosciences is a nanotechnology tools and applications
Company, providing innovative and practical products that support the
growth of the nanotechnology industry. The Company has spent more than a
decade of invention, research and development on patented and
patent-pending nanotechnology products. The core technology is the
NanoArrayer(TM) Benchtop Molecular Printer, a portal to new opportunities
in nanotechnology. The NanoArrayer opens the door to new and important
applications in the biomedical and life sciences markets that lead to
improved quality of life. BioForce continues to target inventions that
further expand the reach of its proprietary technology and expand its
robust patent, trademark and IP portfolio.
BioForce Nanosciences, Inc., the Practical Nanotechnology(TM) company
brings inventions to the marketplace that complement existing innovations,
licensing and acquisitions. BioForce is a wholly owned subsidiary of
BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB). For
more information, visit http://www.bioforcenano.com or contact BioForce at
firstname.lastname@example.org or 515-233-8333.
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in the company's most recent filings with the
Securities and Exchange Commission. The company's actual results could
differ materially from such forward-looking statements. We assume no duty
to update these statements at any future date.
SOURCE BioForce Nanosciences, Inc.